ArticlemBio2019
Cathelicidin Peptides Restrict Bacterial Growth via Membrane Perturbation and Induction of Reactive Oxygen Species.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Disruption ofVirulence · 2026Article
- Antimicrobial Peptides for Diabetic Foot Ulcers and Infections: Current Evidence and Translational Perspectives.International journal of molecular sciences · 2026Review
- Bat-derived antimicrobial peptide MC-CATH3 Confers protection against bacterial infections via a potential ferroptosis-like death process.The Journal of biological chemistry · 2026Article
- Functional characterization of HR-CATH2, a novel cathelicidin fromZoological research · 2026Article
- D-amino acid substitution and cyclization enhance the stability and antimicrobial activity of arginine-rich peptides.Microbiology (Reading, England) · 2026Article
- Pse-T2-Based Short Peptides with Broad-Spectrum Antimicrobial Activity, Stability, and Safety Combat MDRACS infectious diseases · 2025Article
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Rational Design of PCR12mod6, a Cathelicidin-HR-Derived Peptide with Enhanced Dual-Action Antimicrobial and Antioxidant Activity.ACS omega · 2025Article
- Broad-Spectrum Antimicrobial Efficacy of Cyclic Antimicrobial Peptide Against Multidrug-ResistantACS medicinal chemistry letters · 2025Article
- Article
- AMP-IBP5: A Multifunctional Antimicrobial Peptide for Advanced Wound Healing and Inflammatory Skin Disorders.Journal of functional biomaterials · 2025Review
- A novel cathelicidin TS-CATH derived fromComputational and structural biotechnology journal · 2024Article
- Class IIb Microcin MccM Interferes with Oxidative Phosphorylation inACS chemical biology · 2024Article
- Synergistic collaboration between AMPs and non-direct antimicrobial cationic peptides.Nature communications · 2024Article
- Restoring colistin sensitivity in colistin-resistantmSphere · 2024Article
- Article
- Effects of Isalo scorpion cytotoxic peptide on growth, immune performance, and intestinal flora of yellow-feathered broilers.Frontiers in veterinary science · 2024Article
- The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens.Frontiers in pharmacology · 2024Article
- Recent advances in the therapeutic potential of cathelicidins.Frontiers in microbiology · 2024Review
- Unravelling the mechanisms causing murepavadin resistance inFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
All metazoans produce antimicrobial peptides (AMPs) that have both broad antimicrobial and immunomodulatory activity. Cathelicidins are AMPs that preferentially kill Gram-negative bacteria
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.